The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita

被引:75
|
作者
Mihai, Sidonia
Chiriac, Mircea T.
Takahashi, Kazue
Thurman, Joshua M.
Holers, V. Michael
Zillikens, Detlef
Botto, Marina
Sitaru, Cassian
机构
[1] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Dev Immunol,Dept Pediat, Boston, MA 02115 USA
[3] Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80218 USA
[4] Imperial Coll Sch Med, Rheumatol Sect, London, England
来源
JOURNAL OF IMMUNOLOGY | 2007年 / 178卷 / 10期
关键词
D O I
10.4049/jimmunol.178.10.6514
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Epidermolysis bullosa acquisita is a subepidermal blistering disease associated with tissue-bound and circulating autoantibodies against type VII collagen, a major constituent of the dermal-epidermal junction. The passive transfer of Abs against type VII collagen into mice induces a subepidermal blistering disease dependent upon activation of terminal complement components. To further dissect the role of the different complement activation pathways in this model, we injected C1qdeficient, mannan-binding lectin-deficient, and factor B-deficient mice with rabbit Abs against murine type VII collagen. The development and evolution of blistering had a similar pattern in mannan-binding lectin-deficient and control mice and was initially only marginally less extensive in Clq-deficient mice compared with controls. Importantly, factor B-deficient mice developed a delayed and significantly less severe blistering disease compared with factor B-sufficient mice. A significantly lower neutrophilic infiltration was observed in factor B-deficient mice compared with controls and local reconstitution with granulocytes restored the blistering disease in factor B-deficient mice. Our study provides the first direct evidence for the involvement of the alternative Pathway in an autoantibody-induced blistering disease and should facilitate the development of new therapeutic strategies for epidermolysis bullosa acquisita and related autoimmune diseases. The Journal of Immunology, 2007, 178: 6514-6521.
引用
收藏
页码:6514 / 6521
页数:8
相关论文
共 50 条
  • [41] The complement receptor C5aR2 regulates neutrophil activation and function contributing to neutrophil-driven epidermolysis bullosa acquisita
    Seiler, Daniel L.
    Kaehler, Katja H.
    Kleingarn, Marie
    Sadik, Christian D.
    Bieber, Katja
    Koehl, Joerg
    Ludwig, Ralf J.
    Karsten, Christian M.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita
    Sesarman, Alina
    Sitaru, Ana Gabriela
    Olaru, Florina
    Zillikens, Detlef
    Sitaru, Cassian
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2008, 86 (08): : 951 - 959
  • [43] Susceptibility to experimental Epidermolysis Bullosa Acquisita (EBA) is correlated with expression of Th1 cytokines
    Hammers, C. M.
    Bieber, K.
    Ludwig, R. J.
    Zillikens, D.
    Westermann, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 : S12 - S12
  • [44] Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita
    Alina Sesarman
    Ana Gabriela Sitaru
    Florina Olaru
    Detlef Zillikens
    Cassian Sitaru
    Journal of Molecular Medicine, 2008, 86 : 951 - 959
  • [45] Reduced Skin Blistering in Experimental Epidermolysis Bullosa Acquisita After Anti-TNF Treatment
    Misa Hirose
    Anika Kasprick
    Foteini Beltsiou
    Katharina Schulze Dieckhoff
    Franziska Sophie Schulze
    Unni K J S R L Samavedam
    Jennifer E Hundt
    Hendri H Pas
    Marcel F Jonkman
    Enno Schmidt
    Kathrin Kalies
    Detlef Zillikens
    Ralf J Ludwig
    Katja Bieber
    Molecular Medicine, 2016, 22 : 918 - 926
  • [46] Susceptibility to experimental epidermolysis bullosa acquisita (EBA) is correlated with the expression of Th1 cytokines
    Bieber, K.
    Hammers, C.
    Ludwig, R. J.
    Zillikens, D.
    Westermann, J.
    EXPERIMENTAL DERMATOLOGY, 2009, 18 (03) : 289 - 289
  • [47] Recombinant Soluble CD32 Suppresses Disease Progression in Experimental Epidermolysis Bullosa Acquisita
    Iwata, Hiroaki
    Pipi, Elena
    Moeckel, Nicole
    Sondermann, Peter
    Vorobyev, Artem
    van Beek, Nina
    Zillikens, Detlef
    Ludwig, Ralf J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 (03) : 916 - 919
  • [48] Susceptibility to experimental epidermolysis bullosa acquisita (EBA) is correlated with expression of TH1 cytokines
    Hammers, Christoph Matthias
    Zillikens, Detlef
    Westermann, Juergen
    Bieber, Katja
    Ludwid, Ralf
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (03) : AB12 - AB12
  • [49] Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita
    Koga, Hiroshi
    Kasprick, Anika
    Lopez, Rosa
    Auli, Mariona
    Pont, Merce
    Godessart, Nuria
    Zillikens, Detlef
    Bieber, Katja
    Ludwig, Ralf J.
    Balague, Cristina
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [50] Immunization with different adjuvants alters the disease progression in mice with experimental epidermolysis bullosa acquisita (EBA)
    Bieber, K.
    Sitaru, C.
    Zillikens, D.
    Westermann, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2008, 128 : S5 - S5